Lerodalcibep, a recombinant fusion protein of a PCSK9-binding domain (adnectin) with human albumin, reduced LDL-C by over 50% with monthly subcutaneous injections when administered to heterozygous FH patients over a 24-week study period [38]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.